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Incident Atrial Fibrillation Among Asians, Hispanics, Blacks, and Whites
Summary-Although atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, the underlying mechanisms responsible for its induction and perpetuation remain incompletely understood. Blacks experience a substantially lower rate of AF compared with whites, and the relative strength of this association suggests the mechanism responsible for the race-AF association plays an important role in disease pathogenesis. Because AF rates have only been rigorously compared between black and white patients, it is unclear whether white race confers elevated AF risk or black race affords arrhythmia protection. The present investigation compared incident AF between whites, blacks, Hispanics, and Asians receiving hospital-based medical care in California. A significantly lower hazard of AF was observed among blacks, Hispanics, and Asians compared with whites both before and after controlling for established risk factors. These findings argue against a protective effect unique to black race and instead suggest an unidentified characteristic inherent to white race increases AF risk. In addition, the difference in AF risk between whites and nonwhites was most pronounced in the absence of established AF risk factors. This further suggests that an unknown, alternative disease mechanism is driving these racial differences. As nonwhite racial and ethnic populations within the United States continue to grow, clinicians should be aware of the importance of race in AF prediction and incorporate this knowledge into their care of patients at risk for this frequently encountered disease.
Conclusions-In a large hospital-based cohort, whites have an increased risk of AF whether compared with blacks, Asians, or Hispanics. The heightened AF risk among whites is most pronounced in the absence of cardiovascular comorbidities.
on MRI in the chronic phase of myocardial infarction has been correlated with inducible and spontaneous ventricular tachycardia. It would be of interest to determine whether the gray zone on MRI correlates with IMAT. Early intervention requiring the development of pharmacological or gene therapies to inhibit adipogenesis after myocardial infarction may be of potential therapeutic benefit to patients. Substrate-guided radiofrequency ablations rely on identification of low-voltage areas to identify scar. Similar principles would be valid for "adipose mapping" of critical scar borders involved in reentry. Myocardial structural support resulting from IMAT may be compromised; hence, care must be taken to reduce the risk of catheter-related perforation. The presence of IMAT may be important in pharmacological agent selection. For instance, lipophilic agents such as amiodarone may accumulate within peri-infarct areas to promote antiarrhythmic or proarrhythmic effects. Detailed clinical studies on the effect of antidiabetic agents, which are capable of modulating adipogenesis, by selective stimulation of the peroxisome proliferator-activated receptor-γ transcriptional pathway may be warranted in post-myocardial infarction patients.
Conclusions-Intramyocardial adiposity, in association with myocardial discontinuity within left ventricular scar borders, is a significant factor associated with altered electrophysiological properties, aberrant connexin43 expression, and increased propensity for VT after MI. 3 
Initial Human Feasibility of Infusion Needle Catheter Ablation for Refractory Ventricular Tachycardia
Summary-Recurrent scar-related ventricular tachycardia can be a difficult management problem, associated with significant patient morbidity and the risk of adverse outcomes. Catheter ablation can be very helpful, often in conjunction with antiarrhythmic drug therapy. One of the most significant limitations of catheter ablation, however, is the inability to create sufficient myocardial ablation lesions to interrupt arrhythmogenic substrate that is deep to the endocardium. This series demonstrates the first human experience with an extendable/retractable needle at the tip capable of creating deeper ablations and mapping intramyocardial substrate. In patients with frequent ventricular tachycardia refractory to both catheter ablation and antiarrhythmic drugs, use of the needle catheter permitted intramyocardial mapping and delivery of intramyocardial ablation in all patients, and clinical improvement in most patients. Complications included heart block in 2 patients, which was anticipated based on the location of the ventricular tachycardia substrate, and cardiac perforation in 1 patient, which was thought to be related to the transseptal puncture. Use of this catheter appears to be feasible with an acceptable complication risk and the possibility of benefit in patients with treatment-refractory ventricular tachycardia.
Conclusions-Intramyocardial infusion-needle catheter ablation is feasible and permits control of some VTs that have been refractory to conventional catheter ablation therapy, warranting further study. 4 
In Utero Diagnosis of Long QT Syndrome by Magnetocardiography
Summary-Long QT syndrome (LQTS) is among the most common causes of sudden cardiac death in the young. Although its role in sudden infant death syndrome has been known for more than a decade, a very recent study by Crotti and colleagues suggests that LQTS may also be responsible for >10% of unexplained fetal death. This finding implies that many lives might be saved if LQTS could be accurately diagnosed and effectively treated in utero. Our study demonstrates that both are possible. Using fetal magnetocardiography (fMCG), the magnetic analog of ECG, we show that fetal QTc has diagnostic value for identification of fetuses with LQTS and prognostic value for prediction of a severe phenotype. In addition, fMCG was invaluable for definitive detection of the signature lethal rhythm of LQTS, Torsades de Pointes. The fMCG findings not only prompted successful in utero pharmacological treatment to restore sinus rhythm and postpone the delivery of a premature fetus, but also guided anticipatory neonatal care. Because of the known association between LQTS and low heart rate, some fetuses with an isolated finding of low-for-gestational-age heart rate (< 3%) were referred for fMCG testing and were found to have LQTS. This led to the identification of LQTS in several unsuspecting first-degree relatives. Currently, fMCG is not readily accessible to clinicians because of the cost and complexity of the instrumentation; however, a new technology, based on atomic magnetometers, has the potential to rectify this situation.
Conclusions-Corrected QT prolongation (≥490 ms) assessed by fMCG accurately identified LQTS in utero; extreme corrected QT prolongation (≥620 ms) predicted Torsade de Pointes. FMCG can play a critical role in the diagnosis and management of fetuses at risk of LQTS.
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Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A CompetingRisk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study
Summary-Atrial fibrillation (AF) increases overall mortality. A better understanding of the mechanisms of death in AF patients is required to further refine approaches to reducing the mortality associated with AF. The Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) study (which compared dabigatran etexilate to warfarin), with a mean follow-up of 2 years, provided the opportunity to study causes of deaths and their predictors among a representative set of >18 000 AF patients undergoing anticoagulation. Deaths (1371 deaths), their causes, and major events during follow-up were prospectively collected and blindly adjudicated, and predictors of cause of death were evaluated with competing-risk analysis. Dabigatran significantly reduced vascular-related mortality compared with warfarin but had no effect on other causes of death, which constituted the vast majority (up to 90%) of deaths in this study. This implies that future improvements in antithrombotic treatments may lead to few additional reductions in overall mortality among patients with AF. In contrast, intervening in other mechanisms such as mitigating ventricular remodeling and comprehensive management of cardiovascular risk factors and comorbidities may be more effective in eventually decreasing the 2 most common causes of death in AF patients: sudden cardiac death and death from progressive heart failure. Our results also emphasize the prognostic importance of nonfatal stroke and bleeding events.
Conclusions-The majority of deaths are not related to stroke in a contemporary anticoagulated atrial fibrillation population. These results emphasize the need to identify interventions beyond effective anticoagulation to further reduce mortality in atrial fibrillation. the world. Therefore, preventing, recognizing, avoiding, or treating procedure-related complications is of utmost importance. As the procedure has moved from select centers and select hands to a more a mainstream procedure, the efficacy and safety of the procedure has had a paradigm shift. Currently, the complication rates reported are between 1% and 8%. We assessed the frequency and predictors of inhospital complications in an everyday-clinical-practice population of patients undergoing atrial fibrillation ablation to determine in-hospital mortality associated with atrial fibrillation ablation and to assess the association between annual operator volume and hospital volume with adverse outcomes. The overall frequency of complications was 6.29% with combined cardiac complications (2.54%) being the most frequent. These complications were followed by vascular complications (1.53%), respiratory complications (1.3%), and neurological complications (1.02%). The in-hospital mortality was 0.46%. Annual operator (<25 procedures) and hospital volume (<50 procedures) were significantly associated with adverse outcomes. There was a small (nonsignificant) rise in overall complication rates. We also found that the majority of the procedures were performed by low-volume operators. We propose setting up a national registry to further assess the safety of the procedure, real-world patterns in complications, and evaluation of other unusual adverse events. Finally, a volume threshold considered optimum for the operators and hospital should be ascertained to enhance the safety of the procedure. This could be a stepping stone to establish atrial fibrillation centers of excellence.
Conclusions-The overall complication rate was 6.29% in patients undergoing AF ablation. There was a significant association between operator and hospital volume and adverse outcomes. This suggests a need for future research into identifying the safety measures in AF ablations and instituting appropriate interventions to improve overall AF ablation outcomes. Summary-Atrial fibrillation is associated with hyperactivity of renin-angiotensin II signaling, enhanced oxidant stress, and increased activity of the multifunctional Ca 2+ and calmodulindependent protein kinase II (CaMKII). Excessive CaMKII activity promotes arrhythmia initiation by enhancing Ca 2+ leak from intracellular stores. We recently identified a mechanism whereby CaMKII is activated by oxidation of regulatory domain methionines in response to angiotensin II stimulation and, motivated by these findings, developed new mouse models to test the potential role of oxidation-activated CaMKII in atrial fibrillation. We identified increased oxidized CaMKII in atria from patients with atrial fibrillation compared with nonfibrillating control subjects and determined that atrial fibrillation patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers did not have increased atrial oxidized CaMKII. These findings suggest that CaMKII is oxidized by the renin-angiotensin II pathway and is associated with atrial fibrillation in the subgroup of patients not treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Angiotensin IIinfused mice also showed increased atrial oxidized CaMKII and high rates of atrial fibrillation after rapid right atrial pacing. In contrast, genetically engineered mice with oxidation-resistant CaMKII and mice with atrial overexpression of a methionine-reducing enzyme, methionine sulfoxide reductase A, were resistant to atrial fibrillation induction, intracellular Ca 2+ leak, and angiotensin II infusioninduced increases in oxidized CaMKII. These findings suggest that CaMKII is a critical component of a proarrhythmic oxidant pathway and that CaMKII inhibition could be an effective antioxidant and antiarrhythmic therapy.
Conclusions-Our studies suggest that CaMKII is a molecular signal that couples increased reactive oxygen species with AF and that therapeutic strategies to decrease oxidized CaMKII may prevent or reduce AF. 8 
Frequency and Determinants of Implantable Cardioverter Defibrillator Deployment Among Primary Prevention Candidates With Subsequent Sudden Cardiac Arrest in the Community
Summary-The implantable cardioverter defibrillator (ICD) represents a significant advance for the prevention of sudden cardiac death (SCD). Although clinical guidelines recommend the use of an ICD for primary prevention of SCD among specific patients with low ejection fraction, the extent of its use among those who experience SCD in the community has not been investigated. Using a prospective population-based approach in a large US community, we identified SCD case subjects who would have been eligible for a primary ICD based on echocardiograms performed before the SCD event and using relevant, time-dependent guideline criteria. We found that among cases with assessment of ejection fraction before the occurrence of SCD, 20% would have been eligible for a primary prevention ICD; however, among this eligible subgroup of subjects, only 13% received a primary prevention ICD. The ICD nonrecipients were older than the recipients, and approximately one fourth of them had associated comorbidities such as dementia or advanced renal disease. Further detailed investigations are needed to understand the role of additional factors that affect the decision-making process for primary prevention ICD implantation, such as socioeconomic factors, health insurance, patient preference, and clinical practice patterns.
Conclusions-Only one fifth of the sudden cardiac arrest cases in the community were eligible for a primary prevention ICD before the event, but among these, a small proportion (13%) were actually implanted. Although older age and comorbidity may explain nondeployment in a subgroup of these cases, other determinants such as socioeconomic factors, health insurance, patient preference, and clinical practice patterns warrant further detailed investigation. Summary-Although the risk of appropriate implantable cardioverter-defibrillator therapy is important in patients with Brugada syndrome implanted for resuscitated sudden cardiac arrest (48% at 10 years) and syncope (19% at 10 years), risk stratification remains a challenge in asymptomatic patients with Brugada syndrome. Although low, the event rate is not nil (1%/y). The successful prevention of sudden cardiac death by device implantation is often paramount in the cardiologist's mind, but our study shows that the decision to offer implantable cardioverter-defibrillators to these patients is not straightforward because of a 36% risk of complication. The main issue remains lead failure (29% at 10 years). As a consequence, the risk of inappropriate shock is important (37% at 10 years), as is the risk inherent to lead extraction. However, paying particular attention at implantation (R wave >5 mV), programming (long interval to detection duration, high ventricular fibrillation zone [>210-220 bpm]), and follow-up (implantable cardioverter-defibrillator with remote monitoring capabilities) reduces the risk of inappropriate shock.
Conclusions-Appropriate therapies are more prevalent in symptomatic Brugada syndrome patients but are not insignificant in asymptomatic patients (1%/y). Optimal implantable cardioverter-defibrillator programming and follow-up dramatically reduce inappropriate shock. However, lead failure remains a major problem in this population.
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Inositol 1, 4, 5-Trisphosphate Receptors and Human Left Ventricular Myocytes
Summary-The function of inositol 1,4,5-trisphosphate receptors (IP3Rs) in the human heart is largely unknown and may have important implications in the modulation of myocardial performance and rhythm disturbances. IP3Rs may partly regulate the electric and mechanical properties of cardiomyocytes, contributing to the control of the electric stability and inotropic state of the myocardium. In this study, we have identified that IP3Rs are expressed and operative in nonfailing human left ventricular myocytes and are upregulated in failing human left ventricular myocytes. After Gαq-protein-coupled receptor activation, the Ca 2+ mobilized from the sarcoplasmic reticulum by IP3Rs contributes to the decrease in resting membrane potential, prolongation of the action potential, and incidence of early afterdepolarizations. Ca 2+ transient amplitude and myocyte shortening are enhanced, and extrasystolic and dysregulated Ca 2+ elevations and contractions are apparent. These defects in the electric and mechanical behavior of human cardiomyocytes result in increased developed tension and electric disorders of the myocardium. Thus, the Gαq-protein-coupled receptor/IP3R effector pathway offers inotropic reserve, which is hindered by electric instability and contractile abnormalities.
Conclusions-The Gαq-protein/coupled receptor/IP3R axis modulates the electromechanical properties of the human myocardium and its propensity to develop arrhythmias.
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Brugada Syndrome Behind Complete Right Bundle-Branch Block
Summary-Brugada syndrome (BS) and complete right bundle-branch block (CRBBB) can coexist. CRBBB can completely mask BS, but simultaneous diagnosis has never been attempted. This study represents the first series describing this phenomenon. In 11 patients who had BS and CRBBB, BS was diagnosed before the development of CRBBB, on the resolution of CRBBB, or from new characteristic ST-segment changes that could be attributable to BS. The QRS duration was more prolonged and the amplitude of R in V 1 was larger in the patients with BS and CRBBB compared with ageand sex-matched control subjects. In BS patients with CRBBB, relief of CRBBB, repeated ECG recordings, or pharmacological tests can be useful to demonstrate typical ST-segment elevation. The prevalence, mechanism, and clinical significance of the combination of CRBBB and BS need to be determined.
Conclusions-BS can coexist behind CRBBB, and CRBBB can completely mask BS. BS might be demonstrated by relief of CRBBB or by spontaneous or drug-induced ST-segment elevation. The prevalence, mechanism, and clinical significance of a combination of CRBBB and BS are yet to be determined.
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Safety and Efficacy of a Totally Subcutaneous Implantable-Cardioverter Defibrillator
Summary-The implantable cardioverter-defibrillator decreases mortality in selected populations at increased risk of sudden cardiac death. This benefit is mitigated in part by both short-and long-term complications of the defibrillator implant or system, most commonly associated with transvenous leads. In an effort to minimize lead complications, a totally subcutaneous implantable cardioverter-defibrillator system was developed to avoid the need for transvenous lead placement. The present study is the first large prospective trial of this system, and it was designed to evaluate the effectiveness and safety of the subcutaneous implantable cardioverter-defibrillator. The primary effectiveness and safety end points were met, demonstrating a very high termination rate of induced ventricular tachyarrhythmias and an acceptably low complication rate. Moreover, the defibrillation efficacy is stable over time for both spontaneous and induced arrhythmias. The device effectively withholds shocks for most supraventricular arrhythmias, particularly if the conditional zone is activated for discrimination. To achieve reliable defibrillation and arrhythmia discrimination, the device delivers only high-energy shocks (80 J), and the time to therapy is typically ≈20 seconds. This is consistent with the longer time to therapy now recommended to improve patient outcomes on the basis of the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy study. The results of the present study indicate that the subcutaneous implantable cardioverter-defibrillator is a viable alternative to transvenous systems among patients who do not require pacing therapy for heart failure, bradycardia, or ventricular tachycardia.
Conclusions-The findings support the efficacy and safety of the S-ICD System for the treatment of life-threatening ventricular arrhythmias. 13 
Influence of Diabetes Mellitus on Inappropriate and Appropriate Implantable Cardioverter-Defibrillator Therapy and Mortality in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial
Summary-Diabetes mellitus is frequently associated with ischemic heart disease and may alter the disease process. Data gathered on patients with heart failure and diabetes mellitus are highly relevant to improve our current knowledge in the field. We aimed to investigate the influence of innovative implantable cardioverter-defibrillator programming in patients with diabetes mellitus and to determine whether these patients derive benefit similar to that in patients without diabetes mellitus. It is of great importance to evaluate the differences in the risk of inappropriate therapy and appropriate therapy and subsequent outcome in patients with diabetes mellitus to provide tailored treatment strategies. Our novel finding is that both patients with and without diabetes mellitus gain a reduction of inappropriate therapy using innovative implantable cardioverter-defibrillator programming with high-rate cutoff or delayed therapy. However, diabetes mellitus was associated with a significantly lower risk of inappropriate therapy caused by supraventricular tachycardia and sinus tachycardia, whereas the risk of atrial fibrillation was similar in patients with and without diabetes mellitus. These findings suggest that different mechanisms are responsible for inappropriate therapy and that diabetics may have higher thresholds for implantable cardioverter-defibrillator firing as a result of reduced autonomic cardiovascular reflexes. The risk of appropriate therapy was higher in diabetic patients and was associated with increased mortality, suggesting that patients with diabetes mellitus may be more prone to develop ventricular tachyarrhythmias and may be more vulnerable to appropriate ICD shock therapy than nondiabetics. Our findings may help improve ICD programming in patients with diabetes mellitus and may raise awareness about the importance of optimized treatment strategy after an appropriate shock to improve clinical outcome.
Conclusions-Innovative high-rate cutoff or delayed ICD programming was associated with a reduction in inappropriate therapy in Summary-In patients with sick sinus syndrome, the occurrence of atrial fibrillation (AF) after pacemaker implantation is associated with an increased risk of stroke, systemic embolism, heart failure, and mortality. The present study, a single-blinded, 2×2 factorial randomized, multicenter trial in 385 patients with sick sinus syndrome and paroxysmal AF and a 3.1-year follow-up, investigated whether long-term atrial pacing at the right atrial appendage versus the low right atrial septum with or without a continuous atrial overdrive pacing algorithm can prevent the development of persistent AF. Our results showed that neither low right atrial septal pacing to reduce P-wave duration nor the use of continuous atrial overdrive pacing to increase atrial pacing significantly affect the long-term development of persistent AF. No clinical variables could predict any potential benefit of either alternative site pacing or rate on progression to persistent AF. Other secondary end points, including AF burden, atrial high-rate episode >6 minutes, quality of life, and adverse events, were unaffected by the atrial pacing site and rate. In conclusions, among patients with sick sinus syndrome and paroxysmal AF who required pacemaker implantation, the use of an alternative atrial pacing site at the lower right atrial septum or continuous atrial overdrive pacing provided no incremental benefit to atrial-based pacing with minimized ventricular pacing in preventing the development of persistent AF.
Conclusions-In patients with paroxysmal AF and sick sinus syndrome requiring pacemaker implantation, an alternative atrial pacing site at the RA septum or continuous atrial overdrive pacing did not prevent the development of persistent AF.
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Timing of Myocardial Trpm7 Deletion During Cardiogenesis Variably Disrupts Adult Ventricular Function, Conduction, and Repolarization
Summary-Transient receptor potential (TRP) channels are a superfamily of broadly expressed ion channels with diverse physiological roles. TRPC1, TRPC3, andTRPC6 have been shown to contribute to cardiac hypertrophy and heart failure in mouse models. Human mutations in TRPM4 have been linked to progressive familial heart block and conduction system disease. TRPM7 is unique in that it is an ion channel fused to a kinase domain. It is highly expressed in adult heart and first expressed in embryonic myocardium. Recent work has found TRPM7 to be important for atrial fibroblast differentiation in human atrial fibrillation. Thus, there is an emerging story describing an important connection between TRPM7 and human heart disease, particularly electrophysiological diseases. Our study provides insight into how loss of Trpm7 function may alter adult cardiac electrophysiology and function. We find that genetic deletion of Trpm7 during cardiogenesis modifies the myocardial transcriptional profile and variably disrupts adult ventricular function, inducing heart block, impaired repolarization, and ventricular arrhythmias. We show that this is associated with However, rates of appropriate shock were similar across age groups, with a mean of 5.1 and 12.0 events per 100 person-years for primary and secondary prevention cohorts, respectively. Competing risk analysis verified an increase in all-cause mortality but no significant decline in appropriate shocks with advanced age. Furthermore, inappropriate therapy and complications were similar regardless of age. These results suggest that decisions regarding ICD candidacy should not be based on age alone. Cardiovascular and noncardiovascular hospitalizations were elevated in the elderly, reflecting a greater impact of comorbidities. Consideration of prognostic factors that predict mortality in conjunction with individualized clinical judgment will help to identify older patients who are more likely to benefit from ICD implantation.
Conclusions-Whereas elderly patients exhibited increased mortality after ICD implantation, rates of appropriate device shocks were similar across age groups. Decisions regarding ICD candidacy should not be based on age alone but should consider factors that predispose to mortality despite defibrillator implantation.
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Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation
Summary-Warfarin effectively prevents stroke in patients with atrial fibrillation but has a narrow therapeutic window with an
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increased risk of stroke and bleeding when above or below the time in therapeutic range (TTR) of international normalized ratio of 2.0 to 3.0. There are large variations of TTR across individuals, sites, and countries, which are related to patient outcomes. The global Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial randomized 18 201 patients with atrial fibrillation in 1034 centers in 39 countries to apixaban or warfarin at a median TTR of 66% but with substantial variation between countries, centers, and patients. The overall results showed that apixaban reduced stroke by 21%, death by 11%, and major bleeding by 31%. Key additional questions involved the extent of benefits that remained in centers with higher TTR. The challenge in determining this issue is the lack of a comparable measure of the level of anticoagulation in both the apixaban and warfarin arms. We developed a new method in which, for each patient, a center average TTR was estimated with the use of a linear mixed model based on real TTRs in the warfarin-treated patients, with a fixed effect for country and random effect for center. For each patient, an individual TTR was also predicted with the use of a linear mixed effects model including patient characteristics as well. The results of these analyses consistently showed that the benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appeared similar across the range of centers' and patients' predicted quality of international normalized ratio control.
Conclusions-The benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers' and patients' predicted quality of international normalized ratio control.
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Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Results of a Prospective, Multinational Registry
Summary-Although current recommendations restrict sports participation for patients with an implantable cardioverter-defibrillator (ICD), the risks are unknown. In this study, athletes with ICDs (age, 10-60 years) participating in organized (n=328) or high-risk (n=44) sports were followed up prospectively for median of 30 months, with sports-related and clinical data obtained by phone interview and medical records at baseline, if a shock occurred, and every 6 months. Median age was 33 years (89 subjects <20 years of age); 33% were female; and 42% had a pre-ICD history of ventricular arrhythmia. Sixty subjects were competitive athletes (varsity/junior varsity/traveling team). Running, basketball, and soccer were the most common sports. There were no occurrences of either primary end point-death or resuscitated arrest or arrhythmia-or shock-related injury-during sports. Shocks were not uncommon; there were 49 shocks in 37 participants (10% of study population) during competition/practice, 39 shocks in 29 participants (8%) during other physical activity, and 33 shocks in 24 participants (6%) at rest. In 8 ventricular arrhythmia episodes (device defined), multiple shocks were received: 1 at rest, 4 during competition/practice, and 3 during other physical activity. The ICD terminated all episodes. Freedom from lead malfunction was 97% at 5 years (from implantation) and 90% at 10 years, similar to that reported in unselected populations. In summary, many athletes with ICDs can engage in vigorous and competitive sports without physical injury or failure to terminate the arrhythmia, despite the occurrence of both inappropriate and appropriate shocks. These data provide a basis for more informed physician and patient decision making in terms of sports participation for athletes with ICDs.
Conclusions-Many athletes with ICDs can engage in vigorous and competitive sports without physical injury or failure to terminate the arrhythmia despite the occurrence of both inappropriate and appropriate shocks. These data provide a basis for more informed physician and patient decision making in terms of sports participation for athletes with ICDs.
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Upregulation of the HyperpolarizationActivated Current Increases Pacemaker Activity of the Sinoatrial Node and Heart Rate During Pregnancy in Mice
Summary-An increased incidence of cardiac arrhythmias is observed during pregnancy. This may have significant consequences on the well-being of the mother and the fetus. In fact, during pregnancy the heart rate significantly increases, thus raising the susceptibility to arrhythmias. This is particularly true in the third semester, when sinus tachycardia becomes very common. Indeed, >50% of pregnant women exhibit a form of arrhythmia and ectopic beats. The mechanisms for the increase in heart rate and subsequent arrhythmia risks have been largely unexplored. In the present study we used a mouse model of pregnancy to explore the positive chronotropic effect in pregnancy, and we report one of the main underlying ionic mechanisms responsible for heart rate increase. First, we show that our mouse model of pregnancy reproduces the increased heart rate observed in pregnancy in humans and importantly that this increase is intrinsic to the heart and not secondary to alterations in autonomic tone, arterial blood pressure, or circulating catecholamine levels. We then demonstrate that pregnancy is associated with accelerated automaticity of the sinoatrial node cells through enhanced density of the funny current (I f ), 1 of the major ionic currents modulating pacemaker activity of the heart. Our results thus provide novel and functional insight into mechanisms of pregnancy-induced increase in heart rate. Additional work will be directed toward examining how these changes may initiate arrhythmias during pregnancy. As the number of pregnancies in women at an advanced maternal age-with more comorbidity-continues to rise, this issue is becoming even more relevant.
Conclusions-This study shows that an increase in I f current density contributes to the acceleration of sinoatrial node automaticity and explains, in part, the higher HR observed in pregnancy.
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Results From a Single-Blind, Randomized Study Comparing the Impact of Different Ablation Approaches on Long-Term Procedure Outcome in Coexistent Atrial Fibrillation and Flutter (APPROVAL)
Summary-This randomized, single-blinded study compared the impact of different ablation strategies on the long-term procedure outcomes such as arrhythmia recurrence and change in quality of life in patients with coexistent atrial fibrillation and atrial flutter (AFL).
In the presence of concurrent atrial fibrillation and AFL, although the literature is limited, the reported results support a variety of procedural approaches. They include either pulmonary vein antrum isolation for atrial fibrillation or cavotricuspid isthmus ablation for AFL or a combined approach of pulmonary vein antrum isolation plus cavotricuspid isthmus ablation. The optimal strategy remains unclear, prompting the present study. Our findings clearly suggested that atrial fibrillation ablation with or without AFL ablation is more effective than AFL ablation alone in achieving recurrence-free survival and improving quality of life. Furthermore, our results indicated that pulmonary vein antrum isolation alone may have an efficacy comparable e382 Circulation
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to that pulmonary vein antrum isolation plus AFL ablation in controlling both arrhythmias and improving quality of life. Also worth mentioning is the fact that this was the first study with patients blinded to the procedure type to show that improvement in quality of life correlated with clinical freedom from arrhythmia recurrence. Although this study had certain limitations, it was an attempt to explore the best ablation option for the elimination of arrhythmias in patients with coexistent atrial fibrillation and AFL. There is a pressing need for optimization of a safe and effective ablation approach that would successfully cure both arrhythmias and save the patients from the cost and the stress of recurrences and repeat ablations. Our study is a step forward in that direction.
Conclusions-In coexistent AF and AFL, lower recurrence rate and better quality of life are associated with AF ablation only or AF+AFL ablation than with lone AFL ablation. Furthermore, quality of life directly correlates with freedom from arrhythmia, as shown in this study for the first time in patients blinded to the procedure. 
MicroRNA29: A Mechanistic Contributor and Potential Biomarker in Atrial Fibrillation
Summary-Despite a variety of advances, the management of atrial fibrillation (AF) remains challenging. Congestive heart failure (CHF) is a major predisposing factor for AF, and atrial fibrosis is known to be a significant component of the CHF-induced AF substrate. MicroRNAs (miRs) are small RNA sequences (18-22 nucleotides) that regulate protein transcription and mRNA stability.
In the present study, we studied the role of miR29 as a potential contributor to the AF-maintaining fibrotic substrate caused by CHF, as well as a possible AF/CHF biomarker. We found that atrial miR29 is rapidly downregulated in a canine model of tachycardia-induced CHF, followed by upregulation of its extracellular matrix targets collagen I/III and fibrillin. Lentiviral-mediated knockdown of the most prevalent isoform miR29b in atrial fibroblasts (to mimic CHFinduced downregulation) increased the expression of collagen I/III and fibrillin, whereas miR29b enhancement suppressed extracellular matrix protein expression. MiR29b plasma levels were significantly decreased in patients with CHF or AF and were further decreased in patients with both AF and CHF, whereas 3 other miRs (miR21, miR133, and miR15) showed weak or absent relations with AF and CHF. MiR29b expression was also reduced in the atria of chronic AF versus sinus rhythm patients. In vivo knockdown of miR29b in mice via intravenous administration of a cardiotropic adenoassociated viral vector significantly increased atrial COL1A1 mRNA expression and cardiac tissue collagen content. We conclude that miR29 may contribute to the fibrotic AF-maintaining substrate in CHF and is altered in the plasma of patients with AF and/or CHF. Thus, miR29 shows promise as an AF biomarker and is a potential therapeutic target for AF prevention.
Conclusions-MiR29 likely plays a role in atrial fibrotic remodeling and may have value as a biomarker and/or therapeutic target. Results of 12 917 nonagenarians reveal a mortality rate of 1.87%, a complication rate of 6.31%, an average length of stay of 4.3 days, and mean charges of $41 373, all modest increases relative to patients aged 70 to 79 years. Regression analysis demonstrates that nonelective admission and comorbidity are greater predictors of poor outcomes than increasing age. These findings suggest that pacemaker implantation in nonagenarians is safe. Decisions regarding pacemaker implantation should be individualized and age should not be a barrier to implantation.
Conclusions-Although increasing age predicts worsening outcomes in the elderly, the absolute rates are modest, even in nonagenarians, and comorbidity is a stronger predictor.
23
Management of Ventricular Tachycardia in the Setting of a Dedicated Unit for the Treatment of Complex Ventricular Arrhythmias: Long-Term Outcome After Ablation
Summary-Catheter ablation plays a relevant role in the treatment of drug-refractory ventricular tachycardia (VT) episodes, recurrent implantable cardioverter-defibrillator shocks, lowering VT recurrence and improving quality of life. Data about the effects of catheter ablation on survival are still controversial. We implemented a multidisciplinary model, aiming for multiskilled management of this critical population from patients' admittance to electrophysiological procedure, therapy optimization, and close follow-up. We provide the largest clinical experience to date investigating the potential benefit of catheter ablation for the treatment of VT in patients with any type of structural heart disease. Risk stratification on admission was the first step of our approach to VT management, and it allowed the identification of patients at high risk of developing an adverse outcome, who were treated subsequently by a comprehensive and multidisciplinary approach. Five hundred twenty-eight patients were treated by ablation; after a median follow-up of 26 months, VT recurrence rate and cardiac mortality were significantly lower in patients without any VT inducibility at programmed stimulation after the procedure than in those with induction of nonclinical VT and those with persistence of clinical VT inducibility. On the basis of multivariate analysis, postprocedural inducibility of index VT was independently associated with both VT recurrence and cardiac mortality. Catheter ablation favorably affects VT recurrence, hospitalization, and survival in a large cohort of patients with VT; therefore, it might be proposed as elective treatment for VT even in patients with advanced heart disease and severe comorbidities.
Conclusions-Within a dedicated VT unit, catheter ablation prevents long-term VT recurrences, which may favorably affect survival in a large number of patients who have VT.
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Reuse of Pacemakers: Comparison of Short and Long-term Performance
Summary-In developing economies, there are patients in whom pacemaker implantation is delayed or not performed because they cannot afford a device. Reused devices have been a solution for many patients in these countries. Until now, publications on pacemaker reuse have lacked sufficient scientific evidence to prove that reuse is safe and feasible. Reasonable questions on reuse have been raised, and reuse has even been judged to be unethical. In the last few years, however, renewed interest in pacemaker reuse has stirred up an old controversy. The question of whether reuse is safe and feasible needs an answer because many patients are receiving these devices. We have carefully analyzed the data and have concluded that reused devices are safe if handled properly. We are the first to establish proper definitions for the end points analyzed and to provide solid evidence with a sufficient number of patients to confirm our findings. This article challenges the general view that resterilizing pacemakers can be deleterious and unethical, provides a proven protocol for resterilization, and tries to establish a channel for communication between industrialized countries and developing countries on one of the main issues of modern medicine: cost and availability of medical care. Conclusions-In patients with a left ventricular ejection fraction ≤35%, symptoms of heart failure, and a QRS duration <120 milliseconds, cardiac resynchronization therapy did not improve clinical outcomes or left ventricular remodeling and was associated with potential harm.
Conclusions
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Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of Age
Summary-Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden death in the young and is responsible for heart failure and stroke-related disability and death in adults of all ages. Although HCM is known to be compatible with normal longevity, a common perception also remains that this disease is ultimately associated with unrelenting progression throughout a patient's lifetime. Therefore, whether patients of more advanced ages harbor disease-related risks similar to young patients is unresolved. By assembling and analyzing 428 HCM patients presenting at ≥60 years of age to 2 major centers, we were able to clarify the natural history of this complex disease at more advanced ages. Over follow-up, 279 patients (65%) survived to 73±7 years of age, and 149 (35%) died at 80±8 years. Only 16 patients (3.7%) had HCM-related mortality events (0.64%/y), including embolic stroke (n=6), progressive heart failure or transplantation (n=3), postoperative complications (n=2), and arrhythmic sudden death events (n=5, including 2 who died; 0.2%/y). Notably, all-cause mortality was increased compared with a matched US general population, predominantly resulting from non-HCM-related causes. Consequently, these data suggest an inverse relationship between the inherent risks from HCM and achieving advanced age, with survival itself generally declaring lower-risk status. Patients surviving into the seventh decade with this genetic disease are at low risk for HCM-related mortality and morbidity, including sudden death (even when conventional risk factors are present). These data do not support aggressive prophylactic defibrillator implantation at advanced ages for HCM patients. Indeed, in such older patients, other cardiac or noncardiac comorbidities, as competing modes of death, pose a greater threat to long-term survival.
Conclusions-HCM patients surviving into the seventh decade of life are at low risk for disease-related morbidity/mortality, including sudden death, even with conventional risk factors. These data do not support aggressive prophylactic defibrillator implantation at advanced ages in HCM. Other cardiac or noncardiac comorbidities have a greater impact on survival than HCM in older patients.
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Incident Atrial Fibrillation and Risk of End-Stage Renal Disease in Adults With Chronic Kidney Disease
Summary-Atrial fibrillation frequently occurs among patients with chronic kidney disease (CKD) and is associated with adverse outcomes. In this study, we evaluated the association of incident atrial fibrillation with progression of CKD to end-stage renal disease, defined as the need for dialysis or renal transplant, among a large cohort of adults with CKD. Among 206 229 adults with CKD, 16 463 (8.0%) developed incident atrial fibrillation. Incident atrial fibrillation was independently associated with a 67% increased relative rate of end-stage renal disease, even after adjustment for demographics, cardiovascular risk factors, and pertinent medication use. This association was strong and consistent among all age, race, sex, and CKD category subgroups. Therefore, incident atrial fibrillation may be an important risk factor for progression of CKD to end-stage renal disease. Further study is needed to identify potentially modifiable pathways through which atrial fibrillation leads to a higher risk of progression to end-stage renal disease.
Conclusions-Incident AF is independently associated with increased risk of developing ESRD in adults with CKD. Further study is needed to identify potentially modifiable pathways through which AF leads to a higher risk of progression to ESRD.
28
Late Sodium Current Inhibition Reverses Electromechanical Dysfunction in Human Hypertrophic Cardiomyopathy
Summary-Hypertrophic cardiomyopathy (HCM), despite being the most prevalent monogenic cardiac disorder, remains an orphan of disease-specific pharmacological treatment. Altered electric and mechanical function of cardiac myocytes is credited as a fundamental pathophysiological feature of HCM, responsible for manifestations ranging from ventricular arrhythmogenicity to diastolic dysfunction. To date, however, the cellular basis of electromechanical dysfunction in cardiomyocytes from HCM patients and the presence of related therapeutic targets are unresolved. We compared the electromechanical profile of single cardiomyocytes isolated from the surgical specimens of 26 HCM patients undergoing septal myectomy with those of surgical patients without left ventricular hypertrophy. Using patch-clamp measurements and studies of intracellular calcium fluxes, we identified several alterations in HCM cardiomyocytes, including prolongation of action potential, slower calcium dynamics, and higher diastolic tension, favoring arrhythmogenesis and diastolic dysfunction. Intriguingly, all these anomalies were subtended by a marked increase in the membrane late sodium current, which represents a viable therapeutic target in humans owing to the clinical availability of a selective blocker, ranolazine. Indeed, ranolazine at therapeutic concentrations counteracted most of the abnormalities observed in vitro in HCM cardiomyocytes. Specifically, ranolazine reduced the occurrence of early and delayed afterdepolarizations by shortening action potential duration and ameliorated myocardial diastolic function via normalization of intracellular Ca 2+ dynamics. These findings suggest a beneficial effect of late sodium current inhibition in HCM patients, which may ultimately be relevant for the management of arrhythmias and diastolic dysfunction, providing a strong rationale for future clinical studies assessing the efficacy of ranolazine in this disease.
Conclusions-We highlighted a specific set of functional changes in human HCM myocardium that stem from a complex remodeling process involving alterations of CaMKII-dependent signaling, rather than being a direct consequence of the causal sarcomeric mutations. Among the several ion channel and Ca 2+ i handling proteins changes identified, an enhanced I NaL seems to be a major contributor to the electrophysiological and Ca 2+ i dynamic abnormalities of ventricular myocytes and trabeculae from patients with HCM, suggesting potential therapeutic implications of I NaL inhibition. 29 
